Drug intelligence / Profile preview

LP-20

Development stage
Preclinical
Modality
Nanoparticles → Drug Delivery Systems, Peptides
Administration
Systemic
01

Overview

The identifier "LP-20" is a non-specific term used across various scientific and medical contexts to refer to distinct entities. In one instance, LP-20 is described as a lipopeptide constructed nanomicelle. This nanomicelle is designed to combat multidrug-resistant Gram-negative bacterial pneumonia by modulating membrane curvature and inducing dynamic membrane fission. Its mechanism involves multitargeting bacterial components such as lipopolysaccharides, phosphoethanolamine, phosphatidylglycerol, and cardiolipin, leading to accelerated and enhanced antibacterial activity against clinically isolated ESKAPE strains, including multidrug-resistant pathogens, with low resistance risk. Preclinical studies in myositis mice with Escherichia coli MDR and pneumonia mice with Klebsiella pneumoniae have shown its effectiveness and ignorable toxicity. In a different context, LP-20 refers to a 20 mM concentration of L-proline, an amino acid, utilized as a supplement in Tris-egg yolk extender for the cryopreservation of Azeri water buffalo bull semen. This L-proline concentration has been observed to improve sperm viability, motility parameters, and reduce oxidative stress by enhancing antioxidant enzyme levels (TAC, SOD, GSH, GPx) and decreasing malondialdehyde (MDA) levels. Furthermore, LP-20 designates a specific liquid crystalline phase, comprising 20% (w/w) water and 20% (w/w) medium-chain mono/diglycerides (MCG). This formulation is under investigation for its capacity to optimize the cutaneous delivery of paclitaxel, an anticancer drug. Studies have shown that this LP-20 formulation provides the highest paclitaxel cutaneous delivery (threefold compared to a drug solution) and exhibits efficient cytotoxicity against fibroblasts in vitro. Lastly, LP-20 also identifies a locked parallel plate/screw construct, specifically locked parallel screws at a 20° triple pelvic osteotomy (TPO) angle. This construct is a medical device used in veterinary orthopedic surgery for the fixation of experimentally induced rotational osteotomies in canine ilia. Biomechanical evaluations demonstrated that LP-20 constructs significantly reduced screw loosening and exhibited larger yield loads compared to nonlocked or locked diverging constructs.

02

Targets

PG (Prostaglandin)

Beyond the preview

Go deeper on LP-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-20.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call